Ultralife(ULBI) 2023 Earnings Summary
Bullish Points:
1. Revenues for Q2 2023 increased significantly to $42,692,000 compared to $32,126,000 in Q2 2022.
2. Gross profit for Q2 2023 increased to $10,588,000 from $7,646,000 in Q2 2022.
3. Operating income for Q2 2023 increased substantially to $3,665,000 from $793,000 in Q2 2022.
4. Net income for Q2 2023 increased to $3,340,000 from $512,000 in Q2 2022.
5. Cash as of June 30, 2023 increased to $8,283,000 from $5,114,000 as of June 30, 2022.
6. Battery & Energy Products segment sales increased by 12.3% in Q2 2023 compared to Q2 2022.
7. Communications Systems segment sales increased by 344.6% in Q2 2023 compared to Q2 2022.
8. Backlog increased to $110,875, a 40.1% increase compared to the same period last year.
9. Gross margin increased from 23.8% (Q2 2022) to 24.8% (Q2 2023).
10. Company successfully restored data and systems after a ransomware cyberattack in January 2023 without paying ransom.
Bearish Points:
1. Outstanding principal on the Term Loan Facility was $7,167, and $17,630 outstanding on the Revolving Credit Facility as of June 30, 2023.
2. Inventory as of June 30, 2023 increased to $46,063 from $41,192 on December 31, 2022.
3. Property, plant, and equipment, net, decreased to $21,122 as of June 30, 2023 from $21,716 on December 31, 2022.
4. Operating expenses increased by 1.0% to $6,923 in Q2 2023 compared to $6,853 in Q2 2022.
5. Effective tax rate increased to 29.1% in Q2 2023 compared to 25.1% in Q2 2022.
6. January 2023 cyberattack affected sales and advance purchase of certain critical raw materials.
In summary, Ultralife Corporation (ULBI) experienced significant growth in revenues, gross profit, and net income in Q2 2023 compared to Q2 2022. The company also increased its cash position and successfully managed a cyberattack. However, there are concerns regarding the increase in outstanding debt, inventory, and operating expenses, as well as the impact of the cyberattack on sales and raw materials procurement. For more information, you can read the original text of Ultralife's financial report: https://www.sec.gov/Archives/edgar/data/875657/000143774923020795/ulbi20230630_10q.htm
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
